Literature DB >> 10928446

QSAR and CoMFA: a perspective on the practical application to drug discovery.

B L Podlogar1, D M Ferguson.   

Abstract

Mesh：

Year:  2000        PMID： 10928446

Source DB:  PubMed          Journal:  Drug Des Discov        ISSN： 1026-7921


× No keyword cloud information.
  7 in total

1.  TTD: Therapeutic Target Database.

Authors:  X Chen; Z L Ji; Y Z Chen
Journal:  Nucleic Acids Res       Date:  2002-01-01       Impact factor: 16.971

Review 2.  Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.

Authors:  Fabrizio De Ponti; Elisabetta Poluzzi; Andrea Cavalli; Maurizio Recanatini; Nicola Montanaro
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

3.  Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors.

Authors:  Xiao-Yun Lu; Ya-Dong Chen; Ni-yue Sun; Yong-Jun Jiang; Qi-Dong You
Journal:  J Mol Model       Date:  2009-06-20       Impact factor: 1.810

4.  Mechanistic insights into mode of action of novel natural cathepsin L inhibitors.

Authors:  Chetna Tyagi; Sonam Grover; Jaspreet Dhanjal; Sukriti Goyal; Manisha Goyal; Abhinav Grover
Journal:  BMC Genomics       Date:  2013-12-09       Impact factor: 3.969

5.  Advantages and limitations of classic and 3D QSAR approaches in nano-QSAR studies based on biological activity of fullerene derivatives.

Authors:  Karolina Jagiello; Monika Grzonkowska; Marta Swirog; Lucky Ahmed; Bakhtiyor Rasulev; Aggelos Avramopoulos; Manthos G Papadopoulos; Jerzy Leszczynski; Tomasz Puzyn
Journal:  J Nanopart Res       Date:  2016-08-29       Impact factor: 2.253

6.  Integration of Ligand-Based and Structure-Based Methods for the Design of Small-Molecule TLR7 Antagonists.

Authors:  Sourav Pal; Uddipta Ghosh Dastidar; Trisha Ghosh; Dipyaman Ganguly; Arindam Talukdar
Journal:  Molecules       Date:  2022-06-23       Impact factor: 4.927

7.  Pharmacophore and molecular docking guided 3D-QSAR study of bacterial enoyl-ACP reductase (FabI) Inhibitors.

Authors:  Xiaoyun Lu; Man Lv; Kun Huang; Ke Ding; Qidong You
Journal:  Int J Mol Sci       Date:  2012-03-20       Impact factor: 6.208
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.